A Phase 4 interventional study of Insulin Glargine and Glimepiride in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 3 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-08-08.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus, Type 2.
Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2, this one is the 18th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2006, is one of 14 in phase 4, and was the 10th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 281 across the 25 interventional studies. Of the 24 that completed or were terminated, 3 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 26 have an industry lead sponsor. The 7 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
186 studies in Diabetes Mellitus, Type 2 by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 183 finished, 46 (25%) have results posted.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 139th largest by enrollment of the 178 interventional ones that give a count, is one of 10 that started in 2006, is one of 75 in phase 4, and was the 30th registered.
Sanofi’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 186 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of a single injection of glulisine before the main meal added to insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs in Type 2 diabetic patients poorly controlled with basal insulin plus OADs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bolus arm
Drug: Insulin Glargine · Drug: Glimepiride · Drug: Insulin Glulisine · Drug: Metformin
Control arm
Drug: Insulin Glargine · Drug: Glimepiride · Drug: Metformin
One daily injection at bedtime
At same dosage as during the run-in period
One bolus given before the main meal
At same dosage as during the run-in period
Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%
Glycosylated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow -up in diabetic patients. this parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c \<7%
Time frame: at the end of treatment (week 24)
Glycosylated Haemoglobin (HbA1c) Value
Time frame: at the end of treatment (week 24)
Change in Glycosylated Haemoglobin (HbA1c) Value
Time frame: from baseline to the end of treatment (week 24)
Daily Mean Plasma Glucose
Time frame: at the end of treatment (week 24)
Change in Daily Mean Plasma Glucose
Time frame: from baseline to the end of treatment (week 24)
Change in Weight
Time frame: from baseline to the end of treatment (week 24)
Daily Dose of Insulin Glargine
Mean of 3 daily doses reported during the week prior to the final visit
Time frame: at the end of treatment (week 24)
Daily Dose of Insulin Glulisine
Mean of 3 daily doses reported during the week prior to the final visit
Time frame: at the end of treatment (week 24)
Rate of Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL
Time frame: during treatment period (12 weeks)
Rate of Nocturnal Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL
Time frame: during treatment period (12 weeks)
Rate of Severe Symptomatic Hypoglycemia
Time frame: during treatment period (12 weeks)
| Milestone | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride |
|---|---|---|
| Started | 0 | 135 |
| Completed | 0 | 125 |
| Not completed | 0 | 10 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Non compliance with treatment procedure | 0 | 1 |
| Withdrew: Sponsor request | 0 | 2 |
| Withdrew: Patient did not meet inclusion criteria | 0 | 1 |
| Withdrew: Patient personal reasons | 0 | 2 |
| Withdrew: Need of insulin with meals | 0 | 1 |
| Milestone | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride |
|---|---|---|
| Started | 49 | 57 |
| Completed | 48 | 56 |
| Not completed | 1 | 1 |
| Withdrew: Non compliance with treatment procedure | 1 | 0 |
| Withdrew: Early termination by error | 0 | 1 |
Glycosylated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow -up in diabetic patients. this parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c \<7%
| percentage of participants | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride |
|---|---|---|
| Patients With Glycosylated Haemoglobin (HbA1c) Value < 7% | 22.4 | 8.8 |
| percent | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride |
|---|---|---|
| Glycosylated Haemoglobin (HbA1c) Value | 7.5 ± 0.64 | 7.8 ± 0.85 |
| percent | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride |
|---|---|---|
| Change in Glycosylated Haemoglobin (HbA1c) Value | -0.37 ± 0.085 | -0.11 ± 0.078 |
| mg/dL | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride |
|---|---|---|
| Daily Mean Plasma Glucose | 154.7 ± 28.62 | 165.8 ± 37.48 |
| mg/dL | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride |
|---|---|---|
| Change in Daily Mean Plasma Glucose | -15.01 ± 3.661 | -2.07 ± 3.384 |
| kg | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride |
|---|---|---|
| Change in Weight | 0.46 ± 0.316 | 0.22 ± 0.293 |
Mean of 3 daily doses reported during the week prior to the final visit
| units of insulin glargine per day | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride |
|---|---|---|
| Daily Dose of Insulin Glargine | 54.7 ± 34.84 | 62.2 ± 34.85 |
Mean of 3 daily doses reported during the week prior to the final visit
| units of insulin glulisine per day | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride |
|---|---|---|
| Daily Dose of Insulin Glulisine | 12.8 ± 6.59 | — |
| Number of hypoglycemia per patient-year | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride |
|---|---|---|
| Rate of Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL | 8.19 ± 14.603 | 7.68 ± 13.996 |
| Number of hypoglycemia per patient-year | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride |
|---|---|---|
| Rate of Nocturnal Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL | 1.62 ± 3.418 | 3.95 ± 9.339 |
| Number of hypoglycemia per patient-year | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride |
|---|---|---|
| Rate of Severe Symptomatic Hypoglycemia | 0.00 ± 0.000 | 0.20 ± 1.096 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | — | 1/49 (2%) | 0/49 (0%) |
| Insulin Glargine+Metformin+Glimepiride | — | 2/57 (3.5%) | 0/57 (0%) |
| Event | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride |
|---|---|---|
| Angina PectorisCardiac disorders | 1/49 | 0/57 |
| Atrial FibrillationCardiac disorders | 1/49 | 0/57 |
| SclerodermaMusculoskeletal and connective tissue disorders | 0/49 | 1/57 |
| Tendon DisorderMusculoskeletal and connective tissue disorders | 0/49 | 1/57 |
| Age Continuous(years) | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride | Total |
|---|---|---|---|
| Mean | 60.6 ± 6.73 | 59.3 ± 8.84 | 59.9 ± 7.92 |
| Sex: Female, Male(Participants) | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride | Total |
|---|---|---|---|
| Female | 29 | 35 | 64 |
| Male | 20 | 22 | 42 |
| Region of Enrollment(participants) | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride | Total |
|---|---|---|---|
| United States | 23 | 27 | 50 |
| United Kingdom | 11 | 14 | 25 |
| Russian Federation | 15 | 16 | 31 |
| Body Mass Index (BMI)(kg/m²) | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride | Total |
|---|---|---|---|
| Mean | 33.2 ± 5.30 | 33.3 ± 4.39 | 33.3 ± 4.80 |
| Daily Mean Plasma Glucose(mg/dL) | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride | Total |
|---|---|---|---|
| Mean | 170.2 ± 27.86 | 167.4 ± 39.41 | 169 ± 34.33 |
| Duration of diabetes(years) | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride | Total |
|---|---|---|---|
| Mean | 12.1 ± 7.29 | 11.0 ± 7.02 | 11.5 ± 7.13 |
| Glycosylated Haemoglobin (HbA1c)(percent) | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride | Total |
|---|---|---|---|
| Mean | 7.8 ± 0.60 | 8.0 ± 0.67 | 7.9 ± 0.64 |
| Weight(kg) | Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride | Insulin Glargine+Metformin+Glimepiride | Total |
|---|---|---|---|
| Mean | 91.5 ± 16.60 | 92.9 ± 17.15 | 92.3 ± 16.83 |
The record gives a start of Jul 2006, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin glulisine